CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
about
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
P2860
CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@ast
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@en
type
label
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@ast
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@en
prefLabel
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@ast
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@en
P2093
P2860
P1433
P1476
CYP1A2--a novel genetic marker ...... ment of breast cancer patients
@en
P2093
Andrea Markkula
Carsten Rose
Christian Ingvar
Helena Jernström
Maria Simonsson
P2860
P2888
P356
10.1186/S12885-016-2284-3
P407
P577
2016-03-31T00:00:00Z
P6179
1026467443